New Rhein Healthcare

Corsair Pharma is focused on developing innovative therapeutic solutions aimed at enhancing the effectiveness of medications for patients. The company is working on a novel prodrug of treprostinil, which is designed to penetrate the skin, enter the bloodstream, and convert quickly to treprostinil in the liver. This approach has the potential to provide effective treatment options with rapid titration for patients suffering from pulmonary arterial hypertension (PAH). By utilizing a once-daily transdermal patch, Corsair Pharma aims to improve patient care and streamline the administration of treatment.

Theranica is a medical device company that has combined neuromodulation therapy with modern wireless technology to develop proprietary wearable solutions that address various medical conditions and disease states. The noninvasive and therapeutic 'smart' patches are controlled by a smartphone app to allow for personalized, portable, and affordable care. The patch consists of a proprietary 'smart' chip that delivers electrical pulses to neuro-modulate the sensory nerves under the skin. The first application of the technology is for treatment of migraine headaches.

Butterfly Medical Ltd is a medical device company based in Yokne'am, Israel, founded in 2014. The company specializes in developing an innovative implantable device designed to treat Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate. This device offers a fast, simple, and minimally invasive alternative to conventional BPH treatments, such as medication and surgery. It can be placed in under ten minutes in an office setting, using local anesthesia and without the need for surgical incisions or tissue removal. This approach aims to provide a long-term solution with minimal side effects, eliminating the need for hospitalization or general anesthesia. Early clinical trials have shown promising results, with effective outcomes in relieving blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies at leading medical centers in Europe to validate its device's efficacy and safety.

American Injectables specializes in the manufacturing of sterile injectable drugs, focusing on ready-to-use pre-filled syringes and vials. The company operates a state-of-the-art facility dedicated to alleviating drug shortages by providing efficient solutions that streamline the preparation and administration of medications in various healthcare settings, including hospitals, outpatient centers, and clinics. By offering these ready-to-use products, American Injectables aims to enhance the value for healthcare professionals and pharmacy departments, ultimately improving patient care and resource management.

Neuraptive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics and medical products for peripheral nerve injuries (PNI). Founded in 2016 and headquartered in Louisville, Colorado, with additional offices in Philadelphia and Lafayette, the company aims to improve patient outcomes following acute nerve injuries and reconstructive surgeries. Its product portfolio includes AxoFuse, a nerve repair system that prevents degeneration and atrophy; AxoTrim, a surgical instrument for nerve preparation; AxoBond, which secures repaired nerves during recovery; and NTX-001, a drug-device product for surgical applications. Neuraptive's products are designed to enhance recovery speed and quality for patients, leveraging advanced microsurgical techniques to address the challenges posed by PNI. The company originated from technology developed at the University of Texas, reflecting its commitment to innovation in the field of nerve repair.

Neuraptive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics and medical products for peripheral nerve injuries (PNI). Founded in 2016 and headquartered in Louisville, Colorado, with additional offices in Philadelphia and Lafayette, the company aims to improve patient outcomes following acute nerve injuries and reconstructive surgeries. Its product portfolio includes AxoFuse, a nerve repair system that prevents degeneration and atrophy; AxoTrim, a surgical instrument for nerve preparation; AxoBond, which secures repaired nerves during recovery; and NTX-001, a drug-device product for surgical applications. Neuraptive's products are designed to enhance recovery speed and quality for patients, leveraging advanced microsurgical techniques to address the challenges posed by PNI. The company originated from technology developed at the University of Texas, reflecting its commitment to innovation in the field of nerve repair.

Softhale is a medical device company dedicated to developing Soft Mist Inhalation (SMI) devices designed for the effective delivery of pharmaceutical drugs to the lungs. The company's inhalable therapeutic devices utilize proprietary technical configurations to spray a propellant-free liquid formulation. This advanced delivery method allows medication to navigate the natural curve of the throat, offering patients the opportunity to inhale the medication more naturally. By ensuring that drugs reach deep into the lungs, Softhale aims to enhance respiratory treatments and provide relief for individuals suffering from chronic respiratory conditions.

Chase Pharmaceuticals (CPC) is engaged in the identification and clinical development of medically improved, commercially promising, treatments for central nervous system (CNS) disease. The Company was incorporated in 2007 to link emerging technical opportunities in the basic neurosciences to the expanding medical needs of those with neuropsychiatric disease. Operations thus focus on selecting product candidates to license-in, adding value by advancing towards global registration, and licensing-out to commercial partners. There success reflects an exceptional ability to select promising drug candidates, intimate knowledge of the development process as well as our ability to devise the most efficient path to regulatory approval. Since inception, CPC has sought to develop novel compounds that could improve the treatment of AD and related neurodegenerative disorders. Alzheimer’s disease constitutes the largest unmet medical need in neuropsychiatry. No emerging therapies have clearly demonstrated the potential to fulfill this medical need. Symptoms include an increasing loss of memory and other cognitive functions later combined with a variety of neuropsychiatric and behavioral disturbances. Progression is relentless, typically leading to death within 10 to 15 years. AD is now recognized as the third leading killer in the U.S. It is estimated that the 37 million afflicted worldwide cost society over $600 billion annually. As the population ages, this burden will rapidly climb to unsustainable levels. Although US sales of Alzheimer’s disease medications last year topped $4.7 billion, none of the current treatments improve symptoms more than marginally. Moreover, tolerability is poor, dose titration prolonged, and dropout rates high. Chase founders have invented and patented a unique combination of proven, currently marketed pharmaceuticals that we believe will benefit the symptomatic treatment of AD.

Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.